$21B or bust! AbbVie ensures its blockbuster US marathon on Humira will run into 2023
AbbVie has finished another big section in its great wall of protective IP deals that will keep the world’s biggest blockbuster unmarked by biosimilar competition in the US for 5 long years.
Six months after AbbVie struck a deal with Amgen that allows a knockoff of Humira to hit US shores on January 31, 2023, Samsung Bioepis and Merck signed off on an agreement to unveil their biosimilar on June 30, 2023. In most countries in the EU, though, the debut will come this fall, on October 16.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
